New options of intravesical instillation therapy in bladder cancer

Česká verzia

Authors: Antonín Brisuda
Published in the journal: Ces Urol 2018; 22(4): 251-256
Category: Review article

Summary

New technologies are becoming a point of interest in the treatment of very high risk urinary bladder carcinomas as an alternative to radical cystectomy. They are meant to inhance the effectivity of intravesical chemotherapy as an adjuvant treatment after transurethral resection of non-muscle invasice bladder cancer. Another point is that there is currently long lasting shortage of BCG in the Czech Republic and other countries. We present a review of two technologies using thermic effect and radiofrequency. We present an overview of available evidence and a vision of the future.

KEY WORDS

Urinary bladder urothelial carcinoma, intravesical chemotherapy, thermotherapy, radiofreguency.

Zdroje

1. Brausi M, Kurth K, van der Meijden AP, et al. Variability in the recurrence rate at first follow‑up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41: 523.

2. Mariappan P, Finney SM, Head E, et al. Good quality white‑light transurethral resection of bladder tumours (GQ‑WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non‑muscle‑invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int 2012; 109: 1666.

3. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta‑analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa‑pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016; 69(2): 231–244.

4. Järvinen R, Kaasinen E, Sankila A, et al. Long‑term efficacy of maintenance bacillus Calmette‑Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow‑up. Eur Urol 2009; 56: 260.

5. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus calmette‑guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta‑analysis of the published results of randomized clinical trials. J Urol. 2005; 174: 86.

6. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta‑analysis of the long‑term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette‑Guerin for non‑muscle‑invasive bladder cancer. Eur Urol 2009; 56: 247.

7. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette‑Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta‑analysis of the published results of randomized clinical trials. J Urol. 2002 168(5): 1964–1970.

8. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non‑Muscle‑Invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017; 71(3): 447–461.

9. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. J Urol. 1998; 159: 783–787.

10. Curley SA, Palalon F, Sanders KE, Koshkina NV. The effects of non‑invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. Int J Environ Res Public Health. 2014; 11(9): 9142–9453.

11. Brisuda A, Babjuk M, Stolz J. Intravezikální chemoterapie s využitím tepelné energie u pacientů s uroteliálním karcinomem močového měchýře bez invaze svaloviny – zkušenosti jednoho pracoviště. Ces Urol 2017; 21(2): 122–128.

12. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003; 21(23): 4270–4276.

13. Colombo R, Salonia A, Leib Z, Pavone‑Macaluso M, Engelstein D. Long‑term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‑C alone as adjuvant treatment for non‑muscle‑invasive bladder cancer (NMIBC). BJU Int. 2011; 107: 912–918.

14. Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette‑Guérin for adjuvant treatment of patients with Intermediate- and High‑risk Non‑Muscle‑invasive Bladder Cancer. Eur Urol. 2016; 69(6): 1046–1052.

15. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non‑muscle‑invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81–93.

16. Halachmi S, Moskovitz B, Maffezzini M, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011; 29(3): 259–264.

17. Sousa A, Piñeiro I, Rodríguez S, et al. Recirculant Hyperthermic IntraVEsical Chemotherapy (HIVEC) in intermediate‑high‑risk non‑muscle‑invasive bladder cancer. Int J Hyperthermia. 2016; 32(4): 374–380.